Form 4: VolitionRx Executive Gael Forterre Reports Stock Award and Ownership Changes

Gael Forterre, Chief Commercial Officer of VolitionRx, reports the acquisition of restricted stock units (RSUs) and adjustments to beneficial ownership.

Summary

• On March 1, 2025, Gael Forterre, the Chief Commercial Officer of VolitionRx Ltd, was granted 5,523 restricted stock units (RSUs) under the company's 2024 Stock Incentive Plan.
• These RSUs were awarded in lieu of cash compensation.
• The RSUs vest in three equal installments of 1,841 units on March 1, 2025, April 1, 2025, and May 1, 2025, with further time-based vesting on March 1, 2026, contingent upon continued service.
• Upon vesting, Forterre will receive common stock shares equal to the number of vested RSUs.
• Forterre's direct ownership following the transaction is 162,704 shares.
• He also has indirect ownership of 5,000 shares through his spouse and 32,500 shares through Armorica Partners, LLC, where he is the managing director and sole shareholder.
• Forterre disclaims beneficial ownership of the shares held by Armorica Partners, LLC, except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard executive compensation practice. It's neither particularly positive nor negative from an investment perspective.

Positives

• The award of RSUs to a key executive aligns their interests with the company's performance.
• The vesting schedule encourages continued service and commitment from the executive.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.

Stakeholder Impact

• The RSU award could incentivize the executive to improve company performance, potentially benefiting shareholders.
• The dilution effect of the RSU award on existing shareholders is minimal.

Key Dates